Literature DB >> 7515814

Expression of CD5 and CD38 by human CD5- B cells: requirement for special stimuli.

S Zupo1, M Dono, R Massara, G Taborelli, N Chiorazzi, M Ferrarini.   

Abstract

In this study the mode of expression of CD5 by human tonsillar CD5- B cells after stimulation with different agents was investigated. Resting B cells were separated into CD5+ and CD5- cells and the two cell fractions exposed to phorbol 12-myristate 13-acetate (PMA). CD5- B cells expressed CD5 and maximum CD5 expression was achieved after approximately 60 h of culture. Based upon the proportions of cells that express CD5 as well as those of the cells surviving in culture, it was calculated that 15-25% of the total CD5- B cells were induced to express CD5. Unlike CD5- B cells, CD5+ B cells proliferated vigorously in response to PMA as assessed by [3H]thymidine incorporation and cell cycle analysis in vitro. However, the expression of CD5 by CD5- B cells was not related to the selective expansion of some CD5+ B cells left over as contaminant cells since this occurred in the absence of cell proliferation. Upon exposure to PMA, CD5- B cells remained in the G0-G1 phases of the cell cycle and did not express the Ki67 antigen or incorporate [3H]thymidine. Furthermore, mitomycin C treatment of the CD5- B cells did not prevent CD5 expression. Phenotypic studies disclosed that CD5+ B cells but not CD5- B cells expressed CD39. This finding offered the opportunity to carry out an additional control experiment. Separation of the two populations according to the expression of CD39 confirmed the finding obtained by fractionating the cells into CD5+ and CD5- B cells. The cells induced to express CD5 also expressed CD38 that was not detected on resting CD5- B cells. In this respect, the CD5- B cells that converted into CD5+ cells (inducible CD5+ B cells) resembled the cells from the CD5+ B cell fractions that up-regulated CD5 and also expressed CD38 upon exposure to PMA alone. Another example of coordinate expression of these two antigens was the finding that exposure to PMA in the presence of recombinant interleukin-4 (rIL-4) resulted in inhibition of the expression of CD5 and CD38. Although virtually all of the tonsillar CD5- B cells expressed the CD69 activation marker, no cells other than those co-expressing CD5 and CD38 were induced to express CD5 by PMA alone. Resting CD5- B cells failed to express CD5 and/or CD38 when cultured with PMA in the presence of EL4 T cells and IL-4-free T cell supernatants.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515814     DOI: 10.1002/eji.1830240628

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

2.  Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS).

Authors:  M Kvarnstrom; E Sidorova; J Nilsson; C Ekerfelt; M Vrethem; O Soderberg; M Johansson; A Rosen; J Ernerudh
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes.

Authors:  H H Wortis; M Teutsch; M Higer; J Zheng; D C Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

4.  Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells.

Authors:  Carlo Calissano; Rajendra N Damle; Sonia Marsilio; Xiao-Jie Yan; Sophia Yancopoulos; Gregory Hayes; Claire Emson; Elizabeth J Murphy; Marc K Hellerstein; Cristina Sison; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Ivana Ivanovic; Igor M Dozmorov; Sergio Roa; Matthew D Scharff; Wentian Li; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2011-09-23       Impact factor: 6.354

Review 5.  Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.

Authors:  Walaa Darwiche; Brigitte Gubler; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 6.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

7.  Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.

Authors:  S Hashimoto; M Dono; M Wakai; S L Allen; S M Lichtman; P Schulman; V P Vinciguerra; M Ferrarini; J Silver; N Chiorazzi
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

8.  Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones.

Authors:  Rachael J M Bashford-Rogers; Anne L Palser; Clare Hodkinson; Joanna Baxter; George A Follows; George S Vassiliou; Paul Kellam
Journal:  Exp Hematol       Date:  2016-09-28       Impact factor: 3.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.